Single-chain Fv-streptavidin substantially improved therapeutic index in multistep targeting directed at disialoganglioside GD2.

UNLABELLED Multistep targeting can improve the therapeutic index of antibody-based targeting, particularly relevant to pediatric tumors where acute toxicity and late effects of treatment are major concerns. Neuroblastoma is uniquely suited for such investigations because of its abundance of surface ganglioside GD2. METHODS 5F11scFv (scFv = single-chain variable fragment) was constructed from the variable regions of the heavy (V(H)) and kappa-light (V(L)) chain complementary DNA (cDNA) of anti-GD2 IgM hybridoma 5F11 and ligated to full-length streptavidin cDNA for expression in Escherichia coli. Purified 5F11-scFv-streptavidin (5F11-scFv-SA) was a homotetramer and showed comparable avidity to 5F11 IgM and a 30-fold improvement over monomeric scFv. Biodistribution of 5F11-scFv-SA was studied in nude mice xenografted with neuroblastoma LAN-1. Twenty-four hours after intravenous injection of 300-900 microg 5F11-scFv-SA, 150-450 microg of a thiogalactoside-containing clearing agent, (Gal-NAc)(16)-alpha-S-C(5)H(10)-NH-LC-N-Me-biotin (molecular weight, 8652), were administered intravenously, followed by approximately 2.5 microg (1.85-3.7 MBq) (111)In-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-biotin ((111)In-DOTA-biotin) intravenously 4 h later and clocked as time 0. RESULTS Tumor uptake (percentage of injected dose per gram [%ID/g]) at 2 h was 7 %ID/g and decayed with a half-life of 72 h, whereas blood %ID/g rapidly decreased to <1/500 of that of tumor after the first 24 h. The tumor-to-nontumor (T/NT) ratio at 72 h was high (median, 106; range, 3.4 [kidney] to 1660 [blood]). When the area under the radioactivity curve was computed, the T/NT organ ratio was favorable (4.8 for kidney and 162 for blood). When human and murine tumors were surveyed, the T/NT ratio of (111)In-DOTA-biotin uptake correlated with their levels of GD2 expression as assayed by flow cytometry. Biotinylated polypeptides (bovine serum albumin and vasointestinal peptides) achieved selective tumor targeting when the multistep strategy was applied. CONCLUSION Improvement in the T/NT ratio using pretargeting strategy may increase the efficacy and safety of scFv-based approaches in cancer therapy. Additionally, since biotinylated polypeptides can be rendered tumor selective, a large repertoire of agents can potentially be explored.

[1]  C. Meares,et al.  Pretargeting: general principles; October 10-12, 1996. , 1997, Cancer.

[2]  M. Delgado,et al.  Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) as modulators of both innate and adaptive immunity. , 2002, Critical reviews in oral biology and medicine : an official publication of the American Association of Oral Biologists.

[3]  W. Oyen,et al.  Pretargeting of renal cell carcinoma: improved tumor targeting with a bivalent chelate. , 1999, Cancer research.

[4]  Habib Zaidi,et al.  Therapeutic Applications of Monte Carlo Calculations in Nuclear Medicine , 2002 .

[5]  K. D. Hardman,et al.  Single-chain antigen-binding proteins. , 1988, Science.

[6]  D. Goldenberg Advancing role of radiolabeled antibodies in the therapy of cancer , 2003, Cancer Immunology, Immunotherapy.

[7]  Y. Lin,et al.  A tetravalent single-chain antibody-streptavidin fusion protein for pretargeted lymphoma therapy. , 2000, Cancer research.

[8]  M. Cremonesi,et al.  Biochemical modifications of avidin improve pharmacokinetics and biodistribution, and reduce immunogenicity. , 1998, British Journal of Cancer.

[9]  P. Beaumier,et al.  Clinical optimization of pretargeted radioimmunotherapy with antibody-streptavidin conjugate and 90Y-DOTA-biotin. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[10]  F. Fazio,et al.  Monoclonal antibody pretargetting techniques for tumour localization: the avidin‐biotin system , 1991, Nuclear medicine communications.

[11]  M. Little,et al.  Single-chain antibody streptavidin fusions: tetrameric bifunctional scFv-complexes with biotin binding activity and enhanced affinity to antigen. , 1995, Human antibodies and hybridomas.

[12]  N. Cheung,et al.  Monoclonal antibody-based therapy of neuroblastoma. , 2001, Hematology/oncology clinics of North America.

[13]  P. Zanzonico,et al.  Computational methods in internal radiation dosimetry , 2002 .

[14]  R C Boston,et al.  Conversational SAAM--an interactive program for kinetic analysis of biological systems. , 1981, Computer programs in biomedicine.

[15]  George Sgouros,et al.  Murine S factors for liver, spleen, and kidney. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[16]  G. Denardo,et al.  Antibody phage libraries for the next generation of tumor targeting radioimmunotherapeutics. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[17]  R. Reisfeld,et al.  Lymphokine-activated killer cells targeted by monoclonal antibodies to the disialogangliosides GD2 and GD3 specifically lyse human tumor cells of neuroectodermal origin. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[18]  T. Waldmann,et al.  Pretargeting radioimmunotherapy of a murine model of adult T-cell leukemia with the alpha-emitting radionuclide, bismuth 213. , 2002, Blood.

[19]  M. Goris,et al.  Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[20]  N. Cheung,et al.  Complete tumor ablation with iodine 131-radiolabeled disialoganglioside GD2-specific monoclonal antibody against human neuroblastoma xenografted in nude mice. , 1986, Journal of the National Cancer Institute.

[21]  P. Abrams,et al.  Radioimmunotherapy of Cancer , 2000 .

[22]  R. Bruccoleri,et al.  Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[23]  D. Axworthy,et al.  Evolution of a Pretarget Radioimmunotherapeutic Regimen , 2000 .

[24]  Damon L. Meyer,et al.  A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD20-expressing lymphoma xenografts. , 2001, Blood.

[25]  B. L. Bauer,et al.  Gangliosides: the relevance of current research to neurosurgery. , 1991, Journal of neurosurgery.

[26]  James J. Vincent,et al.  Lowering the isoelectric point of the Fv portion of recombinant immunotoxins leads to decreased nonspecific animal toxicity without affecting antitumor activity. , 2001, Cancer research.

[27]  L. Kostakoglu,et al.  Comparison of the targeting characteristics of various radioimmunoconjugates for radioimmunotherapy of neuroblastoma: dosimetry calculations incorporating cross-organ beta doses. , 1996, Nuclear medicine and biology.

[28]  T. Waldmann,et al.  Pretarget radiotherapy with an anti-CD25 antibody-streptavidin fusion protein was effective in therapy of leukemia/lymphoma xenografts , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[29]  P. Caliceti,et al.  Pre-targeted locoregional radioimmunotherapy with 90Y-biotin in glioma patients: phase I study and preliminary therapeutic results. , 2001, Cancer biotherapy & radiopharmaceuticals.

[30]  M G Stabin,et al.  Re-evaluation of absorbed fractions for photons and electrons in spheres of various sizes. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[31]  N. Cheung,et al.  Anti-idiotypic antibody facilitates scFv chimeric immune receptor gene transduction and clonal expansion of human lymphocytes for tumor therapy. , 2003, Hybridoma and hybridomics.

[32]  D. Fisher,et al.  Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL): initial phase I/II study results. , 2000, Cancer biotherapy & radiopharmaceuticals.

[33]  F. Virzi,et al.  Investigations of avidin and biotin for imaging applications. , 1987, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[34]  N. Cheung,et al.  Anti-idiotypic antibody as the surrogate antigen for cloning scFv and its fusion proteins. , 2002, Hybridoma and hybridomics.

[35]  N. Cheung,et al.  Targeting of ganglioside GD2 monoclonal antibody to neuroblastoma. , 1987, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[36]  P. Beaumier,et al.  Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[37]  N. Cheung,et al.  Monoclonal antibodies to a glycolipid antigen on human neuroblastoma cells. , 1985, Cancer research.